Genmab A/S (NASDAQ:GMAB) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Genmab A/S (NASDAQ:GMAB) from a buy rating to a hold rating in a report released on Saturday.

Several other analysts have also commented on the stock. Truist Financial reaffirmed a “buy” rating and set a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price target on shares of Genmab A/S in a research note on Wednesday, January 28th. Finally, Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.25.

Genmab A/S Stock Down 0.2%

Shares of GMAB opened at $30.90 on Friday. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $35.43. The stock has a fifty day simple moving average of $32.50 and a two-hundred day simple moving average of $29.46. The company has a market capitalization of $19.85 billion, a PE ratio of 13.15, a price-to-earnings-growth ratio of 18.14 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $975.40 million. As a group, equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Several hedge funds have recently made changes to their positions in the business. Alliancebernstein L.P. increased its stake in Genmab A/S by 2.7% during the 3rd quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock worth $335,957,000 after buying an additional 291,538 shares during the period. Orbis Allan Gray Ltd grew its stake in shares of Genmab A/S by 38.7% in the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock worth $163,635,000 after acquiring an additional 2,209,659 shares in the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in shares of Genmab A/S during the third quarter worth $117,063,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Genmab A/S by 5.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock valued at $111,735,000 after acquiring an additional 188,761 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in Genmab A/S by 3.5% in the second quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock valued at $36,575,000 after purchasing an additional 60,504 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.